NCT01974232已完成不适用
A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Platelet count greater than or = to 50,000
研究概览
简要总结
This is a retrospective analysis of children (≤21years old) who received clinical treatment with either Romiplostim or Eltrombopag at 2 medical centers from 2009-2013. The children included in this study were from Weill Medical College of Cornell University, New York, New York and Children's Hospital Orange County, Orange, California
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 19 Months 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients in this study had received prior treatments before the start of TPO treatment including corticosteroids, IVIG, IV anti-D, and/or Rituximab.
排除标准
- •Children who do not have ITP
结局指标
主要结局
Platelet count greater than or = to 50,000
时间窗: on two consecutive weeks
次要结局
- An increase in platelets greater than or = to 20,000 over baseline.(On two consecutive weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pediatric Disease Registry in Essential Thrombocythaemia (ET)Essential Thrombocythemia (ET)NCT01198717Shire60
已完成
不适用
Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.Wiskott-Aldrich SyndromeNCT04350164Federal Research Institute of Pediatric Hematology, Oncology and Immunology67
进行中（未招募）
1 期
A Prospective Follow-Up Study of Children Aged 23 to 25 months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm BirthThis is a prospective, follow-up, designed to provide an assessment of the development of children born to mothers enrolled in the trial of the effectiveness of 17PMedDRA version: 14.1Level: LLTClassification code 10036594Term: Premature birthSystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsEUCTR2011-000105-53-CZKV Pharmaceutical Co.375
已完成
不适用
Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received AlpelisibPIK3CA-Related Overgrowth Spectrum (PROS)NCT04285723Novartis Pharmaceuticals57
已完成
3 期
A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)Human Papillomavirus InfectionNCT01984697Merck Sharp & Dohme LLC1,518